Now six PD-1/L1 inhibitors were approved for treatment of lung cancer, melanoma, breast cancer or lymphoma including nivolumab (Opdivo®), pembrolizumab (Keytruda®), atezolizumab (Tecentrip®), avelumab (Bavencio®), durvalumab (Imfinzi®), and cemiplimab (Libtayo®). This evidence concerns the gene PDCD1 and melanoma.